Nanosonics Limited (ASX:NAN): How Will CORIS Commercialisation Follow FY26 Revenue Growth?

Aditi Sarkar

27 October 2026 10:33 PM AEDT

Nanosonics Limited (ASX:NAN): How Will CORIS Commercialisation Follow FY26 Revenue Growth?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nanosonics Limited (ASX:NAN) reported FY26 revenue of AUD 203.9mn, up 3% YoY.
Global trophon placements increased 9% to 4,230 units; the installed base reached 39,230.
FY26 EBIT was AUD 16.0mn, down 10% YoY, while trophon-only EBIT reached AUD 50.6mn.
Nanosonics ended FY26 with AUD 155.2mn in cash and no debt, ahead of its CORIS rollout.

Nanosonics Limited (ASX:NAN) develops infection-prevention technology for reprocessing medical devices, with its trophon systems used to disinfect ultrasound probes. As the company prepares to expand its product range beyond ultrasound reprocessing, Nanosonics shares finished the 27 October 2026 session at AUD 3.12. Its FY26 results set out the financial contribution of the established trophon business and the planned transition of the CORIS endoscope-reprocessing system from controlled release to broader commercial availability.

Company Business

Nanosonics Limited (ASX:NAN) sells automated high-level disinfection systems, related consumables and support services to healthcare providers. Its principal product family, trophon, reprocesses ultrasound probes between patient procedures. Device sales build an installed fleet that generates subsequent consumables and servicing revenue, making adoption, usage and equipment replacement relevant measures of business activity.

The company operates internationally, with North America a significant market and distribution activity spanning other regions. During FY26 it introduced trophon3 and trophon2 Plus, extending the product range as customers upgrade older systems. Nanosonics is also developing CORIS for the cleaning and reprocessing of flexible endoscopes. That platform addresses a different clinical workflow and requires separate commercial execution, hospital evaluation and training.

Recent Development

In August 2026, Nanosonics Limited (ASX:NAN) published its results for the year ended 30 June 2026. Total trophon unit placements rose 9% year on year to 4,230, while the cumulative global installed base increased 6% to 39,230 devices. North American upgrades grew 32%, reflecting the replacement cycle as newer generations entered the market. These measures describe device activity rather than the rate of future sales.

The CORIS controlled market release had commenced in Australia and the United Kingdom during the second half of FY26, with additional sites in Ireland, the United States and Australia. Management outlined plans for a wider commercial launch in the United Kingdom, Ireland and Australia during H1 FY27, followed by the United States. The proposed rollout includes higher spending on commercial awareness, customer development and implementation support; timing remains dependent on execution.

The company also announced a new on-market share buyback of up to AUD 40mn for FY27, following the completion of an AUD 20mn buyback in FY26. The announced maximum does not indicate that the full amount will necessarily be repurchased.

Financial Performance and Sector Context

Nanosonics Limited (ASX:NAN) recorded FY26 revenue of AUD 203.9mn, compared with AUD 198.6mn in FY25, an increase of 3% YoY. On a constant-currency basis, revenue was AUD 211.5mn, up 6%, showing the effect of exchange rates on reported results. Capital revenue rose 4% to AUD 54.7mn, while recurring revenue increased 2% to AUD 149.2mn. Recurring revenue includes consumables, servicing and spare parts associated with devices already in use.

Reported EBIT declined 10% YoY to AUD 16.0mn. On a constant-currency basis, EBIT was AUD 21.6mn, up 21%. The trophon-only business generated AUD 50.6mn in EBIT, up 5% from FY25, although the wider group also incurred expenditure on CORIS and development programs. Operating expenses were AUD 141.4mn, up 2%; research and development expenditure was AUD 31.8mn. The group reported a 76.9% gross margin, against 78.2% in FY25.

At 30 June 2026, cash and equivalents stood at AUD 155.2mn with no debt. The company said cash generation excluding its completed AUD 20mn share buyback was AUD 13.6mn. Infection-control standards and hospital procurement policies influence demand for reprocessing devices, while product adoption and replacement programs affect capital sales. International currency movements can also change reported revenue and profit independently of local-market activity.

Risks to Consider

Nanosonics Limited (ASX:NAN) faces commercialisation risk as CORIS moves into wider hospital use. Evaluation cycles, clinical workflows, regulatory requirements, product training and customer budgets may affect rollout speed. Increased commercial expenditure could weigh on group earnings before CORIS develops material sales. The established trophon business remains exposed to hardware replacement timing, consumables utilisation, foreign exchange, manufacturing costs and competition. Cash resources provide financing capacity but do not remove operational uncertainty.

What to Watch Next

For Nanosonics Limited (ASX:NAN), FY27 disclosures will help establish the pace of CORIS commercial introductions, the number of active sites and the expenditure needed to support adoption. Other measurable indicators include trophon placements, upgrades, installed-base expansion, recurring revenue and movements in gross margin. Investors can also monitor cash balances and the extent of repurchases under the announced buyback, alongside subsequent financial reporting.

Key Insights

Nanosonics Limited (ASX:NAN) increased FY26 revenue and trophon placements, while reported group EBIT declined and the business continued investing in its next product platform. The large installed trophon fleet supports consumables and service activity, and the company closed FY26 without debt. The timing, cost and commercial adoption of CORIS, together with trophon operating trends, remain central disclosures to follow during FY27.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.